Press release
B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024
Discover the latest drugs and treatment options in the B-Cell Lymphomas Pipeline. Dive into DelveInsight's comprehensive report today! @ B-Cell Lymphomas Pipeline Outlook [https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the B-Cell Lymphomas Pipeline Report
* In September 2024:- Pfizer- The purpose of this study is to learn about the effects of three study medicines [maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL).
* In September 2024:- Genmab- The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY Trademark , GEN3013 and DuoBody Registered -CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
* DelveInsight's B-Cell Lymphomas pipeline report depicts a robust space with 160+ active players working to develop 170+ pipeline therapies for B-Cell Lymphomas treatment.
* The leading B-Cell Lymphomas Companies such as Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co, and others.
* Promising B-Cell Lymphomas Therapies such as Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.
Stay ahead with the most recent pipeline outlook for B-Cell Lymphomas. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ B-Cell Lymphomas Treatment Drugs [https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
B-Cell Lymphoma Emerging Drugs
* Odronextamab: ZAI Lab
Odronextamab is a human IgG4-based bispecific antibody that binds to CD3, a T-cell antigen associated with the T-cell receptor complex, and CD20, a B-cell surface antigen present on normal B cells and several B cell lineage malignancies. Odronextamab is currently being studied in a potentially pivotal Phase 2 study in B-cell non-Hodgkin lymphoma (B-NHL), including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL). In April 2020, Zai Lab obtained exclusive rights to develop and commercialize odronextamab in greater China from Regeneron Pharmaceuticals.
* NKTR-255: Nektar Therapeutics
NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body's innate and adaptive immunity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules as well as to enhance CAR-T therapies. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Large B-cell Lymphoma.
* Zilovertamab Vedotin: Merck Sharp & Dohme LLC
Zilovertamab vedotin is under development for the treatment of solid tumors, blood cancer including advanced or metastatic urothelial carcinoma of renal pelvis, ureter (upper urinary tract), bladder, or urethra, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, triple-negative breast cancer (TNBC), diffuse large B-cell lymphoma, or Richter transformation lymphoma. It is administered through intravenous route of administration. It acts by targeting ROR1 antigens expressing cells. The drug candidate is linked to UC-961-linker-monomethyl auristatin E (MMAE) ADC that preserves the high-affinity binding and specificity of UC-961 and allows for ROR1-targeted intracellular release of MMAE. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
* Abexinostat: Xynomic Pharmaceuticals
Abexinostat (PCI-24781) is under development for the treatment of metastatic renal cell carcinoma, follicular lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, relapsed and refractory mantle cell lymphoma. It is formulated as a capsule and is administered through oral route. It acts by targeting histone deacetylase (HDAC). It was also under development for the treatment of lung cancer, colon cancer, gastric cancer, metastatic colorectal cancer, pancreatic cancer, nasopharyngeal cancer, haematological malignancies such as follicular non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL) as second line of therapy, refractory and relapsed multiple myeloma as first and second line of therapy, refractory and relapsed acute myeloid leukemia, acute lymphoblastic leukemia, high or intermediary-2 risk myelodysplastic syndrome and sarcomas as second line of therapy, fallopian tube cancer, peritoneal cancer, brain tumor and neuroblastoma. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Diffuse Large B-cell Lymphoma.
Explore groundbreaking therapies and clinical trials in the B-Cell Lymphomas Pipeline. Access DelveInsight's detailed report now! @ New B-Cell Lymphomas Drugs [https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical
B-Cell Lymphomas Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of B-Cell Lymphomas Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ B-Cell Lymphomas Market Drivers and Barriers [https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the B-Cell Lymphomas Pipeline Report
* Coverage- Global
* B-Cell Lymphomas Companies- Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co, and others.
* B-Cell Lymphomas Therapies- Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.
* B-Cell Lymphomas Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* B-Cell Lymphomas Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on B-Cell Lymphomas Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ B-Cell Lymphomas Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* B-Cell Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* B-Cell Lymphoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Odronextamab: ZAI Lab
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Abexinostat: Xynomic Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* TG 1801: TG Therapeutics Inc.
* Drug profiles in the detailed report.....
* Inactive Products
* B-Cell Lymphoma Key Companies
* B-Cell Lymphoma Key Products
* B-Cell Lymphoma- Unmet Needs
* B-Cell Lymphoma- Market Drivers and Barriers
* B-Cell Lymphoma- Future Perspectives and Conclusion
* B-Cell Lymphoma Analyst Views
* B-Cell Lymphoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bcell-lymphomas-pipeline-insights-treatment-drugs-clinical-trials-and-companies-2024]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 here
News-ID: 3659610 • Views: …
More Releases from ABNewswire
Floor Boys Introduces Premium Pet-Friendly Flooring Solutions for South Carolina …
Lexington-Based Flooring Specialist Offers Scratch-Resistant, Easy-Clean Flooring Options Perfect for Pet Owners
LEXINGTON, SC - Floor Boys Flooring Professionals, backed by 125+ years of combined experience serving Lexington and surrounding South Carolina communities, announces its expanded focus on pet-friendly flooring solutions designed specifically for homeowners with dogs, cats, and other pets. The company specializes in scratch-resistant luxury vinyl plank (LVP), waterproof carpet, tile, and hardwood alternatives that combine durability with style…
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more.
It is now a lifestyle choice.
Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better.
In areas with seasonal weather, where people can be outside for most of the year, homeowners…
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape.
The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative…
Jacksonville Family Business Expands Concrete Washing Services Amid Growing Prop …
Nubirth Pressure Washing, a family-owned company serving Jacksonville since 2004, reflects the growing demand for specialized exterior property cleaning in Northeast Florida, offering comprehensive surface restoration services.
Jacksonville, FL - The Northeast Florida property maintenance industry has witnessed significant growth in specialized cleaning services as homeowners and businesses prioritize exterior property care. Local family-owned company Nubirth Pressure Washing [https://www.google.com/maps/place/Nubirth+Pressure+Washing/@30.3340387,-81.7122184,17z/data=!3m1!4b1!4m6!3m5!1s0x88e5b9c01d715555:0xd2c2470a4640f2be!8m2!3d30.3340387!4d-81.7122184!16s%2Fg%2F11vk2l_v57!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDgyNS4wIKXMDSoASAFQAw%3D%3D] represents this trend, having served the Jacksonville area since 2004 with comprehensive…
More Releases for Cell
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
Cell Banking Outsourcing Market Report 2018: Segmentation by Type of Bank (Maste …
Global Cell Banking Outsourcing market research report provides company profile for Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY…
